Skip to content

Study · Case report or series · n = 1 · 2014

1 result

Exenatide-induced eosinophilic sclerosing lipogranuloma at the injection site.

Shan SJ, Guo Y

The American Journal of dermatopathology1 Jun 2014Cited by 28 (Europe PMC)

PMID24366197 (opens in a new tab)DOI10.1097/dad.0000000000000036 (opens in a new tab)PepBankPUB-24366197
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    A patient developed injection-site eosinophilic sclerosing lipogranuloma attributed to once-weekly exenatide.

    In plain wordsA patient developed an inflammatory lump at the injection site attributed to once-weekly exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableInjection-site eosinophilic sclerosing lipogranuloma
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated · injectionAs given in this study (human).

    Source sentences

    Summary
    Here, we describe a case of exenatide once weekly induced eosinophilic sclerosing lipogranuloma at the injection site of a 62-year-old patient.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.